Floatz logo

Mycobacteriophage

Mycobacterium Infections

National Jewish HealthActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Mycobacterium Infections cohort.

Asset / SponsorPhaseRating
BACILLUS CALMETTE-GUERIN STRAIN TICE LIVE ANTIGEN
Johns Hopkins University
Phase 2B
Thalidomide
National Center for Research Resources (NCRR)
Phase 2B
CEFOXITIN
The University of Queensland
Phase 2CCC
RIFABUTIN
The University of Queensland
Phase 2CCC
Amoxicillin
The University of Queensland
Phase 2CCC

View all 21 →

Same molecule, other indications

Mycobacteriophage is also rated in:

cystic fibrosisDormant
D
Indicative ·
30 / 100
View asset →
pulmonary non-tuberculous mycobacterial infectionDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →